**Supplementary Material** 



Figure S1. Scanning electron microscopic characterization of PCL/Col (A) and PCL/Fib (B) nanofiber matrices. Scale bar = 2  $\mu$ m.



**Figure S2.** Proliferation of human dermal fibroblasts on nanofiber matrices for up to 7 days (n=4) was determined by MTT assay. \* Statistically significant, p<0.05.



**Figure S3**. The morphology of fibroblasts on PCL/Col (A) and PCL/Fib (B) nanofiber matrices after culture for 24 h. A-B) Fluorescent images of fibroblasts stained with phalloidin-TRITC for intracellular cytoskeleton protein of F-actin (red) and DAPI for nuclei (blue). Scale bar =  $50\mu$ m. C) Quantification of the average cell spreading area on PCL/Col and PCL/Fib nanofiber matrices. \* Statistically significant, *p*<0.05.



**Figure S4**. Representative immunoblot images in western blotting analysis of integrin  $\alpha_2$ ,  $\beta_1$ ,  $\alpha_v$  and  $\alpha_v\beta_3$  in fibroblasts on PCL/Col and PCL/Fib nanofiber matrices without TGF- $\beta_1$ .



**Figure S5.** Morphology and focal adhesion formation of human dermal fibroblasts on PCL/Fib nanofiber matrices with integrin  $\alpha_V$  inhibitor Cilengitide (10µg/mL). A) Fluorescent staining for F-actin (red) with phalloidin-TRITC. B) Immunofluorescent staining for vinculin (green) with FITC-anti-vinculin antibody. C) Overlay of F-actin and vinculin staining. Cell nuclei stained blue with DAPI.

Video S1. Random migration of fibroblasts on PCL/Fib nanofibers cultured either

with (A) or without (B) integrin  $\alpha V$  inhibitor (Inh) Cilengitide (10 $\mu$ g/mL).